Logo Image
Opinion|Videos|February 27, 2026

Fred Saad, MD, highlights phase 1 study of 225Ac-PSMA-Trillium in mCRPC

Fact checked by: Hannah Clarke

Fred Saad, MD, FRCP, highlights the background and key findings from the phase 1 PAnTHa study.

In this video, Fred Saad, MD, FRCP, highlights the background and key findings from the phase 1 PAnTHa study, assessing the investigational alpha-emitting radioligand therapy 225Ac-PSMA-Trillium (BAY 3563254) in patients with metastatic castration-resistant prostate cancer (mCRPC). These results were presented at the 2026 ASCO Genitourinary (GU) Cancers Symposium in San Francisco, California.

Saad is a professor and chief of urology at University of Montreal Hospital Center.

Related Content

Latest CME

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified
Multimedia

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

View more
Radioligand Therapy 101: The Science Behind the Strategy
Multimedia

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

View more
Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis
Video

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

View more
Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease
Video

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

View more